Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trial
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag047 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Takahiro Higashibata und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan. Hauptthemen laut MEDLINE: Cancer Pain, Antiemetics, Analgesics, Opioid, Naltrexone. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Tsukuba.
Abstract (Originalsprache)
Background
Several studies have suggested that naldemedine may reduce opioid-induced constipation (OIC) as well as opioid-induced nausea and vomiting (OINV). This study aimed to investigate prophylactic effects of naldemedine on OINV in patients initiating regular, oral, strong opioids for cancer pain.
Methods
In this preplanned secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial investigating the preventive effects of naldemedine on OIC, eligible patients were randomized in a 1:1 ratio to receive either naldemedine 0.2 mg or placebo once daily for 14 days. The primary endpoint was the complete response (CR) rate, defined as the proportion of patients with no vomiting episodes and no use of rescue antiemetics within the first three days of opioid initiation. The secondary endpoint was the nausea and vomiting score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL).
Results
Of the 103 patients, 48 and 47 patients in each group started protocol treatment, respectively. The CR rate was significantly higher in the naldemedine group than in the placebo group (81.3% vs. 38.3%, P < 0.001). Nausea and vomiting scores on the QLQ-C15-PAL at weeks 1 and 2 were significantly better in the naldemedine group (means 7.1 and 6.4) versus placebo (means 44.6 and 35.3; both P<.001). Within the total effect of naldemedine on the QLQ-C15-PAL nausea and vomiting scores at week 2, the proportion mediated through OIC reduction was 21.9%.
Conclusions
Naldemedine may have intrinsic antiemetic potency to prevent both OIC and OINV. Trial registration https://jrct.niph.go.jp/ (Japan Registry of Clinical Trials) Identifier: jRCTs031200397
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
- Department of Gastroenterology, International University Health and Welfare Graduate School of Medicine, Narita 286-8686, Japan.
- Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, Narita 286-8520, Japan.
- Medical Oncology and Palliative Medicine Department, Toyama University Hospital, Toyama 930-0194, Japan.
- Department of Palliative Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
ORCID-Profile: Takahiro Higashibata, Jun Hamano
Förderung
- University of Tsukuba
Zitieren
APA
Higashibata, T., Kessoku, T., Kajiura, S., Hirakawa, M., Oyamada, S., Ariyoshi, K., Yamada, T., Yamamoto, Y., Moriwaki, T., Nagaoka, H., Takashima, Y., Doki, K., Mathis, B. J., Tanaka, K., Fuyuki, A., Nakajima, A., Ishihara, Y., Hayashi, R., Ando, T., …, & Hamano, J. (2026). Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trial. The Oncologist. https://doi.org/10.1093/oncolo/oyag047
Vancouver
Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, Ariyoshi K, et al. Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trial. The Oncologist. 2026. doi:10.1093/oncolo/oyag047
BibTeX
@article{Higashibata2026,
author = {Higashibata, Takahiro and Kessoku, Takaomi and Kajiura, Shinya and Hirakawa, Mami and Oyamada, Shunsuke and Ariyoshi, Keisuke and Yamada, Takeshi and Yamamoto, Yoshiyuki and Moriwaki, Toshikazu and Nagaoka, Hiroka and Takashima, Yasuyuki and Doki, Kosuke and Mathis, Bryan J and Tanaka, Kosuke and Fuyuki, Akiko and Nakajima, Atsushi and Ishihara, Yo and Hayashi, Ryuji and Ando, Takayuki and Kobayashi, Yuko and Izawa, Naoki and Horie, Yoshiki and Morita, Tatsuya and Hamano, Jun},
title = {Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trial},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag047}
}
EUVIMED